Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Net Income (2016 - 2025)

Assembly Biosciences has reported Net Income over the past 11 years, most recently at $22.1 million for Q4 2025.

  • Quarterly results put Net Income at $22.1 million for Q4 2025, up 313.74% from a year ago — trailing twelve months through Dec 2025 was -$6.1 million (up 84.76% YoY), and the annual figure for FY2025 was -$6.1 million, up 84.76%.
  • Net Income for Q4 2025 was $22.1 million at Assembly Biosciences, up from -$9.2 million in the prior quarter.
  • Over the last five years, Net Income for ASMB hit a ceiling of $22.1 million in Q4 2025 and a floor of -$62.8 million in Q4 2021.
  • Median Net Income over the past 5 years was -$15.7 million (2023), compared with a mean of -$16.7 million.
  • Biggest five-year swings in Net Income: crashed 461.45% in 2021 and later skyrocketed 313.74% in 2025.
  • Assembly Biosciences' Net Income stood at -$62.8 million in 2021, then skyrocketed by 64.33% to -$22.4 million in 2022, then surged by 51.05% to -$11.0 million in 2023, then grew by 5.72% to -$10.3 million in 2024, then surged by 313.74% to $22.1 million in 2025.
  • The last three reported values for Net Income were $22.1 million (Q4 2025), -$9.2 million (Q3 2025), and -$10.2 million (Q2 2025) per Business Quant data.